Back to Search Start Over

Transperitoneal vs retroperitoneal laparoscopic radical nephrectomy: a double-arm, parallel-group randomized clinical trial

Authors :
Junyao Liu
Bin Zhang
Peng Qi
Xiaowei Ren
Duo Zheng
Yang He
Xu Zheng
Zhongjin Yue
Ye Li
Ningqiang Yang
Zhiping Wang
Junsheng Bao
Junqiang Tian
Li Yang
Zhenxing Zhai
Lingjun Zuo
Zizhen Hou
Jiaji Wang
Wei Wang
Hong Chang
Junhai Ma
Yunxin Zhang
Zhichun Dong
Zhilong Dong
Ganping Zhong
Hui Cheng
Pengyuan Lei
Zhongming Li
GongJin Wu
Panfeng Shang
Source :
BMC Urology, Vol 24, Iss 1, Pp 1-10 (2024)
Publication Year :
2024
Publisher :
BMC, 2024.

Abstract

Abstract Objective To compare the outcomes of patients undergoing Retroperitoneal laparoscopic Radical nephrectomy (RLRN) and Transperitoneal laparoscopic Radical nephrectomy (TLRN). Methods A total of 120 patients with localized renal cell carcinoma were randomized into either RLRN or TLRN group. Mainly by comparing the patient perioperative related data, surgical specimen integrity, pathological results and tumor results. Results Each group comprised 60 patients. The two group were equivalent in terms of perioperative and pathological outcomes. The mean integrity score was significantly lower in the RLRN group than TLRN group. With a median follow-up of 36.4 months after the operation, Kaplan–Meier survival analysis showed no significant difference between RLRN and TLRN in overall survival (89.8% vs. 88.5%; P = 0.898), recurrence-free survival (77.9% vs. 87.7%; P = 0.180), and cancer-specific survival (91.4% vs. 98.3%; P = 0.153). In clinical T2 subgroup, the recurrence rate and recurrence-free survival in the RLRN group was significantly worse than that in the TLRN group (43.2% vs. 76.7%, P = 0.046). Univariate and multivariate COX regression analysis showed that RLRN (HR: 3.35; 95%CI: 1.12–10.03; P = 0.030), male (HR: 4.01; 95%CI: 1.07–14.99; P = 0.039) and tumor size (HR: 1.23; 95%CI: 1.01–1.51; P = 0.042) were independent risk factor for recurrence-free survival. Conclusions Our study showed that although RLRN versus TLRN had roughly similar efficacy, TLRN outperformed RLRN in terms of surgical specimen integrity. TLRN was also significantly better than RLRN in controlling tumor recurrence for clinical T2 and above cases. Trial registration Chinese Clinical Trial Registry ( https://www.chictr.org.cn/showproj.html?proj=24400 ), identifier: ChiCTR1800014431, date: 13/01/2018.

Details

Language :
English
ISSN :
14712490
Volume :
24
Issue :
1
Database :
Directory of Open Access Journals
Journal :
BMC Urology
Publication Type :
Academic Journal
Accession number :
edsdoj.11a27ff07f64f009f9d357da503e5df
Document Type :
article
Full Text :
https://doi.org/10.1186/s12894-023-01364-w